factor
viii
factor
ix
twin
popul
evid
major
effect
abo
locu
factor
viii
level
j
hum
genet
odonnel
j
boulton
f
man
r
laffan
genotyp
secretor
blood
locu
determin
plasma
vonwillebrand
factor
level
br
j
haematol
meiklejohn
dj
vicker
morrison
er
dijkuisen
r
moor
urbaniak
sj
greav
vivo
platelet
activ
atherothrombot
stroke
determin
polymorph
human
platelet
glycoprotein
iiia
ib
br
j
haematol
down
j
dark
c
modifi
pcrssp
method
identif
abo
blood
group
antigen
eur
j
immunogenet
recent
much
inform
accru
demonstr
close
interact
inflamm
atherosclerosi
thrombosi
sever
casecontrol
studi
repeatedli
confirm
common
clinic
observ
respiratori
tract
infect
often
shortli
preced
accompani
acut
ischem
stroke
acut
myocardi
infarct
larg
popul
base
caseseri
studi
found
rel
risk
ratio
acut
myocardi
infarct
first
day
follow
respiratori
tract
infect
influenza
recogn
major
risk
factor
occurr
acut
ischem
cardiovascular
event
elderli
popul
epidemiolog
evid
consist
prove
decreas
cardiovascular
mortal
follow
vaccin
influenza
thu
far
limit
data
avail
chang
platelet
aggreg
common
viral
respiratori
tract
infect
commonli
due
rhinoviru
coronaviru
infect
case
combin
present
studi
subject
n
eight
male
nine
femal
presum
viral
upper
respiratori
tract
infect
present
bronchiti
pharyng
rhiniti
sinus
recruit
among
hospit
employe
outpati
clinic
patient
suspect
bacteri
infect
receiv
antibiot
therapi
take
nonsteroid
antiinflammatori
agent
aspirin
thienopyridin
warfarin
exclud
peripher
venou
blood
sampl
obtain
time
viral
infect
week
enrol
platelet
surfac
receptor
express
determin
flow
cytometri
use
monoclon
antibodi
glycoprotein
iibiiia
pselectin
previous
describ
platelet
aggreg
determin
use
chronolog
lumiaggregomet
previous
describ
platelet
stimul
adenosin
diphosph
adp
concentr
lm
platelet
aggreg
express
maxim
percent
chang
light
transmitt
baselin
use
platelet
poor
plasma
refer
eight
healthi
volunt
six
male
two
femal
serv
control
mean
age
patient
viral
infect
year
rang
mean
age
control
year
rang
platelet
reactiv
higher
viral
upper
respiratori
tract
infect
measur
low
dose
lm
adpinduc
aggreg
vs
week
p
control
group
p
tabl
similarli
pselectin
express
higher
time
viral
infect
platelet
posit
vs
week
p
control
group
p
signific
differ
pselectin
express
aggreg
week
postinfect
control
group
studi
suggest
subject
suffer
exhibit
increas
platelet
reactiv
activ
demonstr
platelet
sensit
lower
dose
import
agonist
lm
adp
demonstr
differ
maxim
aggreg
induc
higher
dose
lm
adp
find
increas
pselectin
express
consist
presenc
activ
platelet
peripher
venou
circul
viral
ill
data
support
concept
system
proaggregatori
state
shortli
viral
infect
postul
earlier
studi
chang
coagul
platelet
aggreg
lipid
metabol
smooth
muscl
spasm
plaqu
composit
alter
endotheli
function
postul
mechan
underli
observ
pselectin
express
platelet
upon
activ
play
pivot
role
plateletmonocyt
aggreg
format
inflamm
pselectin
essenti
control
platelet
roll
site
vascular
injuri
enhanc
local
thrombu
format
cytokin
tissu
factor
releas
monocyt
circul
activ
platelet
exacerb
atherosclerosi
mice
defici
apolipoprotein
e
effect
reduc
use
pselectindefici
platelet
thu
underlin
import
pselectin
plateletdepend
inflamm
also
higher
level
activ
platelet
consist
document
acut
myocardi
infarct
congest
heart
failur
microangiopath
diabet
mellitu
stroke
sourc
activ
platelet
document
studi
remain
unclear
studi
limit
rel
small
sampl
size
also
find
need
repeat
set
patient
multipl
risk
factor
document
coronari
diseas
greatest
risk
futur
ischem
event
studi
may
help
determin
role
addit
prophylact
platelet
inhibit
patient
viral
upper
respiratori
tract
infect
document
cardiovascular
diseas
conclus
studi
demonstr
viral
respiratori
tract
infect
associ
increas
platelet
reactiv
activ
find
support
proaggregatori
state
may
contribut
higher
rate
myocardi
infarct
stroke
shown
epidemiolog
studi
